Form 4: Phathom Pharmaceuticals Director James N. Topper Reports Beneficial Ownership Changes

Director James N. Topper reports transactions in Phathom Pharmaceuticals stock, including purchases made indirectly through Frazier Life Sciences X, L.P. and other entities.

Summary

• James N. Topper, a director of Phathom Pharmaceuticals, reported changes in beneficial ownership of the company's common stock.
• On May 13, 2025, 1,120 shares were purchased at a weighted average price of $3.1637, with prices ranging from $3.045 to $3.23.
• On May 14, 2025, 6,300 shares were purchased at a weighted average price of $3.3205, with prices ranging from $3.215 to $3.35.
• These purchases were made indirectly through Frazier Life Sciences X, L.P.
• Topper also reported indirect ownership through Frazier Life Sciences IX, L.P., FHMLS IX, L.L.C, and Topper Group III LLC, as well as direct ownership of 32,096 shares.
• Topper disclaims beneficial ownership of shares held by Frazier Life Sciences X, L.P., Frazier Life Sciences IX, L.P. and FHMLS IX, L.L.C except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Positives

• The director's purchases could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's value and prospects.

Comparison to Industry Standards

• It's common for directors of publicly traded companies, especially in the pharmaceutical industry, to have significant holdings in their company's stock.
• These holdings are often accumulated through a combination of direct purchases, stock options, and grants.
• The reported transactions are relatively small in the context of Topper's overall holdings, suggesting routine portfolio adjustments rather than a major shift in investment strategy.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Phathom Pharmaceuticals.
• Increased insider ownership can be viewed positively by shareholders.

Key Dates

Keywords

Phathom Pharmaceuticals, James N. Topper, beneficial ownership, Form 4, insider trading, Frazier Life Sciences, share purchase, director